Haemonetics (NYSE:HAE) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst Says

Haemonetics (NYSE:HAE) had its target price upped by analysts at JPMorgan Chase & Co. from $62.00 to $74.00 in a research note issued to investors on Friday,Benzinga reports. The firm currently has a “neutral” rating on the medical instruments supplier’s stock. JPMorgan Chase & Co.‘s target price would suggest a potential downside of 11.34% from the stock’s previous close.

Several other research firms also recently weighed in on HAE. Wall Street Zen upgraded shares of Haemonetics from a “hold” rating to a “buy” rating in a report on Saturday, December 6th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Haemonetics in a research report on Monday, December 8th. Citigroup cut their price objective on Haemonetics from $78.00 to $64.00 and set a “buy” rating for the company in a research report on Tuesday, October 7th. Needham & Company LLC increased their target price on Haemonetics from $68.00 to $78.00 and gave the company a “buy” rating in a report on Friday, November 7th. Finally, BTIG Research reissued a “buy” rating and issued a $88.00 price target on shares of Haemonetics in a report on Friday, November 21st. One investment analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $80.90.

Haemonetics Stock Performance

NYSE HAE opened at $83.46 on Friday. The business has a 50 day moving average price of $65.38 and a 200 day moving average price of $64.42. The company has a market capitalization of $3.91 billion, a P/E ratio of 24.40, a PEG ratio of 1.58 and a beta of 0.30. Haemonetics has a 1-year low of $47.31 and a 1-year high of $87.32. The company has a debt-to-equity ratio of 1.08, a current ratio of 1.64 and a quick ratio of 1.03.

Haemonetics (NYSE:HAE) last posted its earnings results on Thursday, November 6th. The medical instruments supplier reported $1.27 earnings per share for the quarter, beating the consensus estimate of $1.12 by $0.15. Haemonetics had a return on equity of 27.22% and a net margin of 12.67%.The company had revenue of $327.32 million for the quarter, compared to analyst estimates of $311.61 million. During the same quarter in the prior year, the company earned $1.12 earnings per share. Haemonetics’s revenue was down 5.3% compared to the same quarter last year. Haemonetics has set its FY 2026 guidance at 4.800-5.00 EPS. Sell-side analysts expect that Haemonetics will post 4.55 EPS for the current fiscal year.

Institutional Investors Weigh In On Haemonetics

Several hedge funds have recently made changes to their positions in the business. AQR Capital Management LLC grew its holdings in Haemonetics by 372.8% in the 3rd quarter. AQR Capital Management LLC now owns 2,128,878 shares of the medical instruments supplier’s stock valued at $102,814,000 after buying an additional 1,678,630 shares during the period. River Road Asset Management LLC boosted its position in shares of Haemonetics by 18.7% in the second quarter. River Road Asset Management LLC now owns 1,655,676 shares of the medical instruments supplier’s stock worth $122,586,000 after acquiring an additional 260,624 shares during the last quarter. Geode Capital Management LLC grew its holdings in Haemonetics by 1.9% in the second quarter. Geode Capital Management LLC now owns 1,244,624 shares of the medical instruments supplier’s stock valued at $92,873,000 after purchasing an additional 23,257 shares during the period. Dimensional Fund Advisors LP grew its holdings in Haemonetics by 2.5% in the third quarter. Dimensional Fund Advisors LP now owns 1,099,519 shares of the medical instruments supplier’s stock valued at $53,587,000 after purchasing an additional 26,763 shares during the period. Finally, Royal Bank of Canada increased its position in Haemonetics by 2.3% during the first quarter. Royal Bank of Canada now owns 1,075,604 shares of the medical instruments supplier’s stock worth $68,355,000 after purchasing an additional 24,650 shares during the last quarter. Institutional investors and hedge funds own 99.67% of the company’s stock.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.